Nature, Published online: 26 October 2022; doi:10.1038/s41586-022-05368-8
Patients with resectable clinical stage III or oligometastatic stage IV melanoma were given neoadjuvant relatlimab and nivolumab combination immunotherapy, which induced a high pathologic complete response rate, indicating the efficacy and safety of this regimen.
More News
Is that a giant sandwich? No, it’s the biggest protoplanetary disk in the sky
Author Correction: A high-density and high-confinement tokamak plasma regime for fusion energy – Nature
Superstar porous materials get salty thanks to computer simulations